McKesson Europe fully supports the European Commission’s (EC) evaluation of the General Pharmaceutical Legislation. We strongly believe that the EU’s General Pharmaceutical Legislation is overdue a comprehensive review. The EC needs to utilize this opportunity and make General Pharmaceutical Legislation more effective for European patients.
ME
McKesson Europe
Company · Germany
not in the EU Transparency RegisterThis organization files on consultations without a register number, so its record here is built from its filings alone. Register facts — staff, costs, accreditations — are not available for it.
4
positions filed
in the 583 files tracked
4
legislative files
of 583 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Track McKesson in PolicySpeak: request access →
Work at McKesson Europe? so we know who speaks for it.
Their record over time
McKesson Europe filed 4 positions between 1 Feb 2021 and 22 Apr 2021, across 4 of the 583 legislative files tracked here, attaching a full position paper 2 times.
What they argued
McKesson Europe fully supports the European Commission’s initiative “Digital health data and services – the European health data space”. We would like to use this opportunity to contribute to the ongoing roadmap consultation and flag areas where EU policy action can further be improved.
McKesson Europe welcomes the Proposal for a directive of the European Parliament and of the Council on the resilience of critical entities. The ongoing COVID-19 crisis has demonstrated the need for a strong and coordinated critical infrastructure at national level to ensure rapid and effective intervention in the event of cross-border health threats and future pandemics.
McKesson Europe fully supports EMA’s extended role in addressing public health emergencies including their new role in monitoring medicine shortages. We also support EMA’s definition of medicine shortages as defined in Art. 2 / (d) of the regulation ( “shortage” means that supply of a medicinal product for human use or a medical device does not meet demand for that medicinal product or medical device”).
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put McKesson Europe next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
Showing 5 of 71.
Is this your organization?
Everything on this page comes from McKesson Europe’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.